MCID: FLL041
MIFTS: 46

Follicular Lymphoma 1

Categories: Blood diseases, Rare diseases, Immune diseases, Cancer diseases

Aliases & Classifications for Follicular Lymphoma 1

MalaCards integrated aliases for Follicular Lymphoma 1:

Name: Follicular Lymphoma 1 54 29
Follicular Lymphoma, Susceptibility to, 1 13
Lymphoma, Follicular 69
Follicular Lymphoma 56

Characteristics:

Orphanet epidemiological data:

56
follicular lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

OMIM 54 613024
Orphanet 56 ORPHA545
MESH via Orphanet 43 D008224
UMLS via Orphanet 70 C0024301

Summaries for Follicular Lymphoma 1

OMIM : 54
Follicular non-Hodgkin lymphoma is an indolent B-cell malignancy with an annual incidence exceeding 10,000 cases in the United States (Bohen et al., 2003). One form of susceptibility to follicular lymphoma (FL1) is associated with a region on chromosome 6p21.33. (613024)

MalaCards based summary : Follicular Lymphoma 1, also known as follicular lymphoma, susceptibility to, 1, is related to follicular lymphoma and primary cutaneous follicle center lymphoma, and has symptoms including lymphoma, splenomegaly and fatigue. An important gene associated with Follicular Lymphoma 1 is BCL10 (B-Cell CLL/Lymphoma 10), and among its related pathways/superpathways are Immune response NFAT in immune response and Direct p53 effectors. The drugs Cyclophosphamide and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow.

Related Diseases for Follicular Lymphoma 1

Diseases in the Follicular Lymphoma family:

Follicular Lymphoma 1

Diseases related to Follicular Lymphoma 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
id Related Disease Score Top Affiliating Genes
1 follicular lymphoma 12.6
2 primary cutaneous follicle center lymphoma 11.2
3 lymphoma 11.0
4 histiocytic and dendritic cell cancer 10.9
5 diffuse large b-cell lymphoma 10.7
6 burkitt lymphoma 10.6
7 mantle cell lymphoma 10.6
8 primary effusion lymphoma 10.5
9 lymphoblastic lymphoma 10.4
10 plasmablastic lymphoma 10.4
11 primary central nervous system lymphoma 10.4
12 nodal marginal zone b-cell lymphoma 10.4
13 b-cell lymphomas 10.4
14 biotin-responsive multiple carboxylase deficiencies 10.2 BCL10 BCL6
15 leukemia 10.1
16 lymphomatoid granulomatosis 10.1
17 duodenitis 10.1
18 tang hsi ryu syndrome 10.1 BCL6 IGH
19 sarcoma 10.0
20 pseudotyphus of california 10.0 BCL2 BCL6
21 chronic lymphocytic leukemia 10.0
22 hematopoietic stem cell transplantation 10.0
23 pemphigus 10.0
24 paraneoplastic pemphigus 10.0
25 multiple congenital anomalies mental retardation, growth failure and cleft lip palate 9.9 BCL6 IGH
26 primary cutaneous diffuse large b-cell lymphoma, leg type 9.9
27 splenic marginal zone lymphoma 9.9
28 primary cutaneous marginal zone b-cell lymphoma 9.9
29 alk-positive large b-cell lymphoma 9.9
30 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 9.9
31 diffuse large b-cell lymphoma of the central nervous system 9.9
32 splenic diffuse red pulp small b-cell lymphoma 9.9
33 diffuse large b-cell lymphoma with chronic inflammation 9.9
34 lymphoplasmacytic lymphoma without igm production 9.9
35 leukemia, acute lymphoblastic 3 9.9
36 primary mediastinal large b-cell lymphoma 9.9
37 t-cell/histiocyte rich large b cell lymphoma 9.9
38 intravascular large b-cell lymphoma 9.9
39 blake pouch cyst 9.9 BCL2 BCL6
40 lymphoblastic leukemia 9.9
41 histiocytic sarcoma 9.9
42 progressive multifocal leukoencephalopathy 9.9
43 primary malignant melanoma of the cervix 9.9 BCL2 BCL6
44 hodgkin lymphoma 9.8
45 heterotaxy, visceral, 4, autosomal 9.8 BCL2 BCL6
46 peripheral t-cell lymphoma 9.8
47 conjunctivitis 9.8
48 mucositis 9.8
49 progressive transformation of germinal centers 9.8
50 paraneoplastic polyneuropathy 9.7 BCL2 BCL6

Graphical network of the top 20 diseases related to Follicular Lymphoma 1:



Diseases related to Follicular Lymphoma 1

Symptoms & Phenotypes for Follicular Lymphoma 1

Clinical features from OMIM:

613024

Human phenotypes related to Follicular Lymphoma 1:

56 32 (show all 13)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lymphoma 56 32 Very frequent (99-80%) HP:0002665
2 splenomegaly 56 Frequent (79-30%)
3 fatigue 56 Frequent (79-30%)
4 fever 56 Very frequent (99-80%)
5 lymphadenopathy 56 Very frequent (99-80%)
6 weight loss 56 Very frequent (99-80%)
7 pleural effusion 56 Occasional (29-5%)
8 lymphedema 56 Occasional (29-5%)
9 meningitis 56 Occasional (29-5%)
10 mediastinal lymphadenopathy 56 Very frequent (99-80%)
11 abnormality of the peritoneum 56 Occasional (29-5%)
12 skin nodule 56 Occasional (29-5%)
13 night sweats 56 Very frequent (99-80%)

Drugs & Therapeutics for Follicular Lymphoma 1

Drugs for Follicular Lymphoma 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 475)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
3
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
4
Vidarabine Approved Phase 4,Phase 3,Phase 1,Phase 2 24356-66-9 32326 21704
5
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
6 Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1 52-24-4 5453
7 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
10 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
11 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
15 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
16
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
17
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
18
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
19
Chlorambucil Approved Phase 3 305-03-3 2708
20
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
21
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
23
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
24
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
25
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
26
Ofloxacin Approved Phase 3 82419-36-1 4583
27
Amoxicillin Approved, Vet_approved Phase 3,Phase 2 26787-78-0 33613 2171
28
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
29
Idarubicin Approved Phase 3 58957-92-9 42890
30
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
31
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
32
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
33
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
34
Cytarabine Approved, Investigational Phase 3,Phase 1,Phase 2 147-94-4 6253
35
Etoposide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
36
Ifosfamide Approved Phase 3,Phase 1,Phase 2,Early Phase 1 3778-73-2 3690
37
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
38
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
39
Mechlorethamine Approved Phase 3,Phase 1,Phase 2,Early Phase 1 51-75-2 4033
40
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
41
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
42
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
43
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
44
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
45
Carboplatin Approved Phase 2, Phase 3,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
46
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
47
Teniposide Approved Phase 3,Phase 1,Phase 2 29767-20-2 34698
48
Vindesine Approved Phase 3 59917-39-4, 53643-48-4 40839
49
Acetaminophen Approved Phase 3,Phase 2,Phase 1 103-90-2 1983
50
Diphenhydramine Approved Phase 3,Phase 2,Phase 1 58-73-1, 147-24-0 3100

Interventional clinical trials:

(show top 50) (show all 893)

id Name Status NCT ID Phase Drugs
1 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
2 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
4 Low Grade Lymphoma Recruiting NCT01698866 Phase 4
5 Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma Unknown status NCT00091676 Phase 3
6 Multicentric Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Patients With Stage II−IV Follicular Lymphoma Unknown status NCT00774826 Phase 3 R-CVP;R-CHOP;R-FM
7 Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma Unknown status NCT00028691 Phase 3 chlorambucil
8 Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00022685 Phase 3
9 Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma Unknown status NCT00435955 Phase 3 Rituximab
10 A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients Unknown status NCT01303887 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Prednisolone;Fludarabine
11 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00006250 Phase 3 chlorambucil;dexamethasone;fludarabine phosphate;mitoxantrone hydrochloride
12 Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
13 A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3 Rituximab or Iodine I 131 Tositumomab Therapy
14 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
15 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
16 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
17 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
18 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
19 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
20 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
21 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
22 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
23 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
24 High-Dose Therapy Treatment in Patients With Follicular Lymphoma Completed NCT00696735 Phase 3
25 Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Completed NCT00268983 Phase 3
26 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
27 A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL) Completed NCT01144364 Phase 3 rituximab [Mabthera/Rituxan]
28 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Completed NCT00005589 Phase 3 carmustine;cyclophosphamide;cytarabine;etoposide;melphalan
29 Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy Completed NCT00185393 Phase 3
30 Primary Rituximab and Maintenance Completed NCT00140582 Phase 3 Rituximab
31 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
32 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3 Bendamustine;Standard chemotherapy CHOP + Ritiximab
33 Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients Completed NCT00577993 Phase 3 Fludarabine;Novantrone;Decadron;Rituximab;Interferon;Doxorubicin;Vincristine;Bleomycin;Cyclophosphamide;Etoposide;Cisplatin;Ara-C;Methyl-Prednisolone;Procarbazine;Prednisone
34 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
35 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Completed NCT00004179 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
36 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma Completed NCT00003204 Phase 3 cyclophosphamide;fludarabine phosphate;vincristine sulfate;prednisone
37 A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma Completed NCT01609010 Phase 3 rituximab;interferon-a-2a
38 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
39 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
40 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
41 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
42 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
43 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
44 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
45 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
46 Combination Chemotherapy in Treating Patients With Lymphoma Completed NCT00002835 Phase 3 Carmustine;Cisplatin (CDDP);Cyclophosphamide;Cytarabine (ARA-C);Etoposide (VP-16);Idarubicin;Ifosfamide;Leucovorin Calcium;Melphalan;Methotrexate;Methylprednisolone;mitoxantrone hydrochloride (DHAD);Vincristine Sulfate
47 Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) Completed NCT00147121 Phase 2, Phase 3 Rituximab + Standard CHOP;Rituximab + Bi-weekly CHOP
48 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
49 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
50 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin

Search NIH Clinical Center for Follicular Lymphoma 1

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Follicular Lymphoma 1

Genetic tests related to Follicular Lymphoma 1:

id Genetic test Affiliating Genes
1 Follicular Lymphoma 1 29

Anatomical Context for Follicular Lymphoma 1

MalaCards organs/tissues related to Follicular Lymphoma 1:

39
B Cells, Bone, Bone Marrow, T Cells, Liver, Kidney, Breast

Publications for Follicular Lymphoma 1

Variations for Follicular Lymphoma 1

ClinVar genetic disease variations for Follicular Lymphoma 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.427_428dupTT (p.Glu145Leufs) duplication Pathogenic rs587776632 GRCh37 Chromosome 1, 85733584: 85733585
2 BCL10 NM_003921.4(BCL10): c.231dupA (p.Gly78Argfs) duplication Pathogenic rs587776633 GRCh37 Chromosome 1, 85736416: 85736416
3 BCL10 NM_003921.4(BCL10): c.525_541del17 (p.Val176Asnfs) deletion Pathogenic rs587776634 GRCh37 Chromosome 1, 85733471: 85733487
4 BCL10 NM_003921.4(BCL10): c.410delA (p.Asn137Ilefs) deletion Pathogenic rs587776635 GRCh37 Chromosome 1, 85733602: 85733602
5 BCL10 NM_003921.4(BCL10): c.398dupT (p.Ser134Leufs) duplication Pathogenic rs587776636 GRCh37 Chromosome 1, 85733614: 85733614
6 BCL10 NM_003921.4(BCL10): c.635_637delAAG (p.Glu212del) deletion Pathogenic rs587776637 GRCh37 Chromosome 1, 85733375: 85733377

Expression for Follicular Lymphoma 1

Search GEO for disease gene expression data for Follicular Lymphoma 1.

Pathways for Follicular Lymphoma 1

GO Terms for Follicular Lymphoma 1

Biological processes related to Follicular Lymphoma 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.5 BCL10 BCL6 HLA-DRB1
2 negative regulation of cell growth GO:0030308 9.37 BCL2 BCL6
3 B cell differentiation GO:0030183 9.26 BCL2 BCL6
4 cell morphogenesis GO:0000902 9.16 BCL2 BCL6
5 positive regulation of B cell proliferation GO:0030890 8.96 BCL2 BCL6
6 regulation of apoptotic process GO:0042981 8.8 BCL10 BCL2 BCL6

Molecular functions related to Follicular Lymphoma 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.62 BCL10 BCL2

Sources for Follicular Lymphoma 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....